MedTrace Logo

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

NCT02581189 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 565

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well-controlled conditions. This observational study was the first effectiveness research examining the ABBVIE REGIMEN ± RBV, used according to local label, under real world conditions in Canada in a clinical practice patient population.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Ombitasvir/paritaprevir/ritonavir

Co-formulated tablet

DRUG

Dasabuvir

Tablet

DRUG

Ribavirin

Tablet

Sponsors & Collaborators

  • IST GmbH, Germany

    collaborator INDUSTRY

  • Cato Research

    collaborator INDUSTRY

  • AbbVie

    lead INDUSTRY

Principal Investigators

  • AbbVie Inc. · AbbVie

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-13
Primary Completion
2017-12-20
Completion
2017-12-20

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02581189 on ClinicalTrials.gov